S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:SXTCChina SXT Pharmaceuticals Stock Price, Forecast & News

$0.38
0.00 (-0.77 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.36
Now: $0.38
$0.38
50-Day Range
$0.38
MA: $0.47
$0.57
52-Week Range
$0.34
Now: $0.38
$2.88
Volume2.84 million shs
Average Volume3.81 million shs
Market Capitalization$13.02 million
P/E RatioN/A
Dividend YieldN/A
Beta0.25
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine tablets in China. It provides oral prescription drugs and supplements under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company offers its products to pharmaceutical distributors, pharmaceutical companies, pharmacies, and hospitals through sales representatives. China SXT Pharmaceuticals, Inc. was founded in 2005 and is based in Taizhou, China.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.44 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SXTC
CUSIPN/A
CIKN/A
Phone86-523-8629-8290

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.16 million
Book Value$0.27 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$13.02 million
Next Earnings Date10/30/2020 (Estimated)
OptionableNot Optionable
$0.38
0.00 (-0.77 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SXTC News and Ratings via Email

Sign-up to receive the latest news and ratings for SXTC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











China SXT Pharmaceuticals (NASDAQ:SXTC) Frequently Asked Questions

How has China SXT Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

China SXT Pharmaceuticals' stock was trading at $0.7799 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SXTC stock has decreased by 51.8% and is now trading at $0.3757.
View which stocks have been most impacted by COVID-19
.

When is China SXT Pharmaceuticals' next earnings date?

China SXT Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, October 30th 2020.
View our earnings forecast for China SXT Pharmaceuticals
.

Has China SXT Pharmaceuticals been receiving favorable news coverage?

News articles about SXTC stock have trended negative this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. China SXT Pharmaceuticals earned a daily sentiment score of -2.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about China SXT Pharmaceuticals
.

Are investors shorting China SXT Pharmaceuticals?

China SXT Pharmaceuticals saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 853,600 shares, an increase of 723.9% from the June 15th total of 103,600 shares. Based on an average trading volume of 5,850,000 shares, the short-interest ratio is presently 0.1 days. Approximately 6.3% of the shares of the stock are short sold.
View China SXT Pharmaceuticals' Short Interest
.

Who are some of China SXT Pharmaceuticals' key competitors?

What other stocks do shareholders of China SXT Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other China SXT Pharmaceuticals investors own include HEXO (HEXO), Ibio (IBIO), Remark (MARK), Aytu Bioscience (AYTU), Cocrystal Pharma (COCP), Sintx Technologies (SINT), AIM ImmunoTech (AIM), NF Energy Saving (BIMI), Biocept (BIOC) and CHF Solutions (CHFS).

Who are China SXT Pharmaceuticals' key executives?

China SXT Pharmaceuticals' management team includes the following people:
  • Mr. Feng Zhou, Chairman & CEO (Age 27)
  • Mr. Yao Shi, Chief Financial Officer (Age 38)
  • Dr. Jingzhen Deng, Chief Scientific Officer & COO (Age 59)
  • Mr. Jun Zheng, Exec. Director (Age 40)

What is China SXT Pharmaceuticals' stock symbol?

China SXT Pharmaceuticals trades on the NASDAQ under the ticker symbol "SXTC."

Who are China SXT Pharmaceuticals' major shareholders?

China SXT Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Hudson Bay Capital Management LP (6.35%) and UBS Group AG (0.45%).

Which major investors are buying China SXT Pharmaceuticals stock?

SXTC stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, and Hudson Bay Capital Management LP.

How do I buy shares of China SXT Pharmaceuticals?

Shares of SXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is China SXT Pharmaceuticals' stock price today?

One share of SXTC stock can currently be purchased for approximately $0.38.

How big of a company is China SXT Pharmaceuticals?

China SXT Pharmaceuticals has a market capitalization of $13.02 million and generates $5.16 million in revenue each year.

What is China SXT Pharmaceuticals' official website?

The official website for China SXT Pharmaceuticals is www.sxtchina.com.

How can I contact China SXT Pharmaceuticals?

China SXT Pharmaceuticals' mailing address is 178 TAIDONG ROAD NORTH, TAIZHOU F4, 225300. The company can be reached via phone at 86-523-8629-8290 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.